Fermer le menu



A novel biotherapy targeting the blood-brain barrier dysfunctions to treat patients suffering from disabling neurological diseases



Lys Therapeutics, a French biotech company developing innovative treatments for neurological and neurodegenerative diseases, announced today its first fundraising of 5.5 million euros. This seed round of financing consists of 3 million euros in equity investment led by a consortium of qualified investors including HTH VC, and 2.5 million euros in grants, loans and repayable advances through Bpifrance, as well as other banking institutions.



Lire le communiqué de presse

Plus d'infos